Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Edwards Lifesciences Gets FDA Warning Letter - Medical Product Outsourcing

Edwards Lifesciences Gets FDA Warning Letter

Irvine, CA-based Edwards Lifesciences reported that it has received a warning letter from the FDA stemming from a plant inspection that found problems in its quality-control systems, according to Reuters News Service.

The warning letter prevents new-product approvals for devices related to the quality-control issues, which include complaint handling, documentation and systems training, according to the company that is a manufacturer of heart valves.

The problems surfaced during a routine inspection of the company’s Irvine facility in August. Edwards said it is conducting a broad review of its quality systems and has kept the FDA informed of its efforts.

Despite the letter Edwards does not expect any delays to its clinical trials or product launches.

Edwards aims to introduce a next-generation tissue valve, called Magna, in the third quarter of this year and is also seeking a new indication for its LifeStent product for use in a leg artery.

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters